Kiltearn Partners Llp Has Lowered Helmerich & Payne (HP) Holding By $53.59 Million, Karyopharm Therapeutics (KPTI)’s Sentiment Is 2.4

July 17, 2017 - By Linda Rogers

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $437.84 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

Kiltearn Partners Llp decreased Helmerich & Payne Inc (HP) stake by 50.1% reported in 2016Q4 SEC filing. Kiltearn Partners Llp sold 696,000 shares as Helmerich & Payne Inc (HP)’s stock declined 12.04%. The Kiltearn Partners Llp holds 693,129 shares with $53.65 million value, down from 1.39 million last quarter. Helmerich & Payne Inc now has $6.11B valuation. It closed at $55.35 lastly. It is down 4.51% since July 17, 2016 and is uptrending. It has underperformed by 12.19% the S&P500.

Palo Alto Investors Llc holds 1.72% of its portfolio in Karyopharm Therapeutics Inc for 3.20 million shares. Tfs Capital Llc owns 105,040 shares or 0.26% of their US portfolio. Moreover, Tekla Capital Management Llc has 0.2% invested in the company for 500,324 shares. The Missouri-based Piermont Capital Management Inc. has invested 0.11% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 55,793 shares.

Ratings analysis reveals 100% of Karyopharm Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Karyopharm Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. KPTI was included in 2 notes of analysts from August 18, 2016. Jefferies upgraded the shares of KPTI in report on Tuesday, August 30 to “Buy” rating. The rating was initiated by H.C. Wainwright on Thursday, August 18 with “Buy”.

Analysts await Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings on August, 3. They expect $-0.63 earnings per share, up 25.00% or $0.21 from last year’s $-0.84 per share. After $-0.71 actual earnings per share reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts -11.27% EPS growth.

It closed at $9.44 lastly. It is down 21.19% since July 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.

Among 31 analysts covering Helmerich & Payne (NYSE:HP), 8 have Buy rating, 7 Sell and 16 Hold. Therefore 26% are positive. Helmerich & Payne had 93 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was upgraded by Morgan Stanley on Tuesday, September 6 to “Equal-Weight”. The company was maintained on Friday, September 4 by Credit Suisse. The firm has “Underweight” rating given on Wednesday, August 26 by JP Morgan. The rating was downgraded by BMO Capital Markets to “Underperform” on Wednesday, September 2. Citigroup maintained it with “Sell” rating and $43 target in Friday, September 11 report. The rating was downgraded by Morgan Stanley on Wednesday, June 21 to “Underweight”. The firm earned “Buy” rating on Tuesday, September 8 by Argus Research. On Friday, August 28 the stock rating was upgraded by Stephens to “Overweight”. The stock of Helmerich & Payne, Inc. (NYSE:HP) earned “Sector Perform” rating by Iberia Capital Partners on Monday, September 21. The company was maintained on Monday, May 29 by Stifel Nicolaus.

Kiltearn Partners Llp increased Alleghany Corp Del (NYSE:Y) stake by 17,000 shares to 248,880 valued at $151.35M in 2016Q4. It also upped State Str Corp (NYSE:STT) stake by 57,800 shares and now owns 829,314 shares. Borgwarner Inc (NYSE:BWA) was raised too.

Investors sentiment decreased to 1.08 in Q4 2016. Its down 0.17, from 1.25 in 2016Q3. It is negative, as 40 investors sold HP shares while 179 reduced holdings. 85 funds opened positions while 152 raised stakes. 107.48 million shares or 7.38% less from 116.04 million shares in 2016Q3 were reported. Livforsakringsbolaget Skandia Omsesidigt owns 4,909 shares. State Of Wisconsin Investment Board stated it has 0.01% in Helmerich & Payne, Inc. (NYSE:HP). Boston Ltd reported 314,083 shares. 96,595 were reported by Oppenheimer Close Ltd Co. Profund Advisors Limited Liability Company stated it has 0.04% in Helmerich & Payne, Inc. (NYSE:HP). Reilly Financial Advisors Ltd Llc invested in 0.01% or 400 shares. The Maryland-based Sandy Spring Comml Bank has invested 0.02% in Helmerich & Payne, Inc. (NYSE:HP). Td Asset Mgmt invested in 0.03% or 259,238 shares. First Midwest Comml Bank Tru Division stated it has 0.11% in Helmerich & Payne, Inc. (NYSE:HP). Envestnet Asset Mngmt Inc invested 0.01% in Helmerich & Payne, Inc. (NYSE:HP). Meeder Asset owns 0.08% invested in Helmerich & Payne, Inc. (NYSE:HP) for 10,450 shares. Shelton Cap Management holds 0.07% in Helmerich & Payne, Inc. (NYSE:HP) or 10,205 shares. Natixis holds 7,402 shares or 0.01% of its portfolio. Utah Retirement holds 0.03% of its portfolio in Helmerich & Payne, Inc. (NYSE:HP) for 17,799 shares. Victory Management owns 0.11% invested in Helmerich & Payne, Inc. (NYSE:HP) for 579,162 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: